archive_header_en_20251209152800609.png

icon_20251209152801238.png

Change account information such as the email address and password on the account setting screen common to Confit.

Login required to view

Password required to view

Presentation Information

Session Details

This archive has moved to the member page of The Molecular Biology Society of Japan.<br>Members can access the abstracts via links at the member page of the sites.<br>Please feel free to contact the journal offices for any inquiries.

To browse or post comments, you must log in.

You cannot post comments as it is outside the comment posting period.

This comment has been deleted. You cannot reply to this comment.

Program Type

Boosted tumor immunogenicity by splicing modulation potentiates the response to immune checkpoint therapy

We focus on translational research related to mRNA, including therapeutics development for infectious and neurodegenerative diseases.  mRNA vaccines are now being rapidly and effectively deployed in the context of the COVID-19 pandemic.  Their design, synthesis, optimization, and formulation will be discussed, e.g., how to avoid immune rejection of the foreign nucleic acid. mRNA can also serve as the target for antisense-oligonucleotide (ASO) and small-molecule drugs.  ASOs can be designed to trigger degradation of the mRNA target or to alter how the mRNA is processed from its precursor; ‘Spinraza', e.g., modulates alternative splicing of SMN2 pre-mRNA and has been used to treat &gt;11,000 spinal muscular atrophy (SMA) patients worldwide.  A small-molecule drug, ‘Evrysdi', was recently approved to target the same splicing event in SMA.  Small molecules can be designed to selectively destroy target mRNAs or to alter their processing.  Both platforms will be discussed for various therapeutic applications.

日本分子生物学会年会

The 44th Annual Meeting of the Molecular Biology Society of Japan

The 44th Annual Meeting of the Molecular Biology Society of Japan

[1AS-01-3]Boosted tumor immunogenicity by splicing modulation potentiates the response to immune checkpoint therapy

Keywords:

Password required to view